-FAPI-74
-FAPI-74 是目前在国外临床研究中出现的一款新药或疗法，主要研究方向为Tuberculosis, Pulmonary、Allogeneic Stem Cell Transplantation、Lung Allograft Transplantation、Interstitial Lung Disease。下面汇总了它当前在全球正在招募患者的研究，以及中国患者可以走的申请途径。
18 项
全球在招研究
9 项
已进入 III/IV 期
6 个
开展国家和地区
暂未检索到
中国境内设点
药品与企业信息
研发企业
- University of Pennsylvania
- National Heart, Lung, and Blood Institute (NHLBI)
- KU Leuven
- Universitaire Ziekenhuizen KU Leuven
- UMC Utrecht
- Turku University Hospital
- Children's Hospital Medical Center, Cincinnati
- Tadashi Watabe
汇总自相关试验登记的主要申办方；研究机构申办时会显示相应机构名称。
生产企业
公开药品批准资料或正式说明书暂未提供明确的生产企业信息。
研发企业与生产企业可能不是同一家。研究阶段药品可能尚未公布生产企业；生产企业仅取自美国上市原研药说明书所列企业（不含仿制药），不作推测；仅在其他国家上市的药品暂无法显示。
主要开展国家和地区
比利时、荷兰、芬兰、美国、日本、瑞士
正在招募患者的 -FAPI-74 研究
Multicenter Validation Trial of [18F]AlF-FAPI-74 for PET Imaging of Cancer-associated Fibroblasts Through Fibroblast Activation Protein Inhibitors (FAPI) in Different Tumor Types
II 期 / III 期招募中比利时NCT06782412Prospective Trial of [18F]AlF-FAPI-74 for PET Imaging of Fibroblast Activation Protein in Patients With Endometriosis
不适用招募中比利时NCT07876648FAPI Molecular Imaging for Diagnosis of the CMS4 Unfavorable Colorectal Cancer Subtype
不适用招募中荷兰NCT06191120Colon Cancer Diagnosis With FAPI-PET Imaging
II 期 / III 期招募中芬兰NCT07272772The Investigators Will Evaluate the Diagnostic Performance of [18F]-AlF-FAPI-74 PET/CT in Inflammatory Disorders and Compare it With the Current Gold Standard for Inflammation, FDG PET/CT, in Three Patient Cohort: Patients Presenting With Fever of Unknown Origin, IgG4-RD and AxSpA.
II 期 / III 期招募中比利时NCT0753555418F-Fibroblast Activation Protein Inhibitor (18F-FAPI-74) in Tuberculosis Patients
不适用招募中美国NCT07077213Evaluation Using FAPI-PET Targeting Cancer-associated Fibroblasts
不适用招募中日本NCT05442151Fibroblast Activating Protein (FAP) PET/CT in Adults With Tuberculosis
早期 I 期招募中美国NCT07830771FAPI-74 PET/CT in Adults With Fibrosis
I 期招募中美国NCT06413355[18F]F-FAPI PET/CT and Laparoscopy in Staging Advanced Gastric Cancer
II 期 / III 期招募中荷兰NCT07018661Using 18F-FAPI PET to Detect Metastatic Disease in Patients That Have Gastric or Esophageal Cancer.
III 期招募中美国NCT07217704Pancreatic Cancer Diagnosis With FAPI-PET Imaging
II 期 / III 期招募中芬兰NCT07098598Multimodality Cardiac Imaging for Disease Progression in ATTR-CM
不适用招募中瑞士NCT0711206618F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection
II 期招募中美国NCT06503146The Effect of [18F] F-FAPI PET-CT on Management in Patients With Proximal Cholangiocarcinoma
II 期 / III 期招募中荷兰NCT06355427Fibrotic Disease Activity in Cardiopulmonary Disorders Using 18F-Fibroblast Activation Protein Inhibitor (18F-FAPI-74) PET/CT Imaging
III 期招募中美国NCT07613099Role of the Fibroblast Activation Protein (FAP) as Biomarker of Fibrotic Lung Diseases
II 期招募中比利时NCT06189820Using 18F-FAPI PET to Detect Metastatic Disease in Patients That Have Pancreatic Ductal Adenocarcinoma (PDAC)
III 期招募中美国NCT07217717
中国患者怎么争取用上这款药
目前境内暂未检索到设点，下面几条途径是更现实的选择，每条都有详细的中文做法。
查看完整申请指南同类方向的其他在研新药
本页信息整理自 ClinicalTrials.gov 公开登记数据，仅供参考，不构成医疗建议；是否适合使用该药物，请以专业医生和研究团队的意见为准。